Breathtaking advances begin with outstanding people – from researchers determined to find cures to healthcare providers who deliver extraordinary care to dedicated volunteers and partners who passionately support our mission to defeat cancer. Nothing is more important than people to advance our ability to find better ways to prevent, diagnose and treat cancer.

The OHSU Knight Cancer Institute’s ground-breaking discoveries, combined with the collaborative and pioneering spirit of our faculty, attract many leading cancer experts to OHSU. These clinicians and researchers have helped OHSU earn a reputation as a world leader in cancer research and care. To build on that track record and to find better therapies, we must recruit and retain top scientists and clinicians and provide them with the tools they need to get the job done.

Investing in exceptional faculty is also OHSU’s top strategic priority. These cancer experts attract new talent and produce the discoveries that give cancer patients reason to hope.

How does support help OHSU recruit and retain leading experts in cancer research and care?

Gifts provide current resources and endowed support to fund programs in perpetuity. The OHSU Knight Cancer Institute’s top priorities are to raise support for our Best & Brightest Funds and for endowed faculty positions.

- **Best & Brightest Funds** provide immediate resources for faculty, such as competitive start-up packages for promising scientists. These packages include funds for research, support staff, equipment, salary and laboratory supplies. Funds help build recruitment packages that keep the institute at the forefront of research and care. Gifts of all sizes make a meaningful difference.

- **Endowed faculty positions** attract exceptional candidates, or to honor our most accomplished current faculty. Endowed positions provide outstanding faculty with professional prestige, financial sustainability and the ability to focus on research, new discoveries and mentoring. Endowed positions help ensure the short- and long-term strength of our academic and research programs and further the discovery process. To name and endow a professorship requires an investment of $1 million. Naming and endowing a chair requires $2.5 million.

Our mission is to end cancer as we know it.

With the latest treatments and technologies, hundreds of research studies and approximately 400 clinical trials, the OHSU Knight Cancer Institute is the only cancer center between Sacramento and Seattle designated by the National Cancer Institute — an honor earned only by the nation’s top cancer centers. This distinction is shared among the more than 650 doctors, nurses, scientists and staff who work together at the Knight to reduce the impact of cancer.
What are the OHSU Knight Cancer Institute’s top priorities for future investment in faculty?

- Raise $2.5 million for the John Barry Endowed Fund for Urology, which will endow a chair to advance research and care for the treatment of urologic malignancies, including prostate, bladder and kidney cancers.

- Raise $100,000 in immediate support for the Best & Brightest Fund for Radiation Medicine. These funds will be applied to a recruitment package for a radiation biologist to establish a new research program and develop novel therapeutic approaches that will enhance our ability to treat cancer.

- Raise support over the next five years to enable the recruitment of top cancer experts specializing in breast, head/neck, brain, gastrointestinal and gynecologic cancers as well as lymphoma, melanoma, sarcoma and myeloma.

Breakthroughs in research and clinical advances begin with exceptional people — and excellence attracts excellence. Your support ensures that our cancer investigators and clinicians have the resources they need to make pioneering advances and to translate those discoveries into new treatments that will save and improve human lives.

Who has benefited from Best & Brightest support?

Alan Sandler, M.D., a renowned lung cancer expert, chief of the Division of Hematology and Oncology (2009)

Charles Keller, M.D., pediatric oncologist focused on developing molecularly targeted therapies for rhabdomyosarcoma and medulloblastoma (2010)

OHSU Knight Cancer Institute faculty who hold endowed positions:

Brian Druker, M.D., JELD-WEN Chair of Leukemia Research
Tomasz Beer, M.D., Grover C. Bagby Endowed Chair of Prostate Cancer Research
Alan Sandler, M.D., DeArmond Chair of Clinical Research
Motomi Mori, Ph.D., Walter and Clora Brownfield Professorship in Biostatistics
Kevin Billingsley, M.D., Hedinger Surgical Chair
To Be Appointed, Chair of Basic Science
To Be Appointed, Charles R. and Velma E. Sharp Endowed Professorship
(appointee to have cancer focus and hold appointment in family medicine or public health.)

“Philanthropy is the best tool for progress in science. There’s no question that advances in the years ahead will all come at the hands of dreamers and doers.”

Joe Robertson, M.D., M.B.A.
OHSU President

For more information or to make a gift contact:
Rachel Hunsinger
Director of Development
OHSU Knight Cancer Institute
Mail Code: CR145
3181 SW Sam Jackson Park Rd.
Portland, OR 97239-3098
503 494-8342
hunsinge@ohsu.edu
cancer.ohsufoundation.org
www.ohsu.edu/cancer